Klein Matthew B. 4

What Happened

• Matthew B. Klein, CEO of PTC Therapeutics (PTCT), was credited with 12,500 shares as earned restricted stock units (RSUs) tied to December 2024 performance-based awards; the award is reported at $0.00. Of those, 6,500 RSUs vested immediately on March 11, 2026 and the remaining 6,500 are scheduled to vest on March 11, 2027. On March 12, 2026 Klein disposed of 2,662 shares in an open-market sale at $64.08 per share, generating proceeds of $170,581. The sale was an automatic “sell-to-cover” tied to tax withholding for the vested RSUs (see footnote).

Key Details

• Award (A): 12,500 RSUs earned on 2026-03-11, reported acquisition price $0.00.
  • 6,500 RSUs vested immediately (3/11/2026); 6,500 RSUs scheduled to vest 3/11/2027.
  • These RSUs are earned PSUs from a Dec 2024 grant; each RSU equals one share upon vesting (Footnote F1).
• Sale (S): 2,662 shares sold 2026-03-12 at $64.08, proceeds $170,581.
  • Sale executed automatically to satisfy tax withholding obligations for the vested RSUs per an irrevocable sell-to-cover election (Footnote F2).
• Filing/Timeliness: Form 4 filed 2026-03-13 reporting transactions dated 3/11–3/12; filing appears timely (not marked late).
• Shares owned after the transactions: not specified in the provided excerpt of the filing.

Context

• This transaction combines a routine compensation award (performance RSUs certified by the compensation committee) with an automatic sell-to-cover for taxes. Sell-to-cover transactions are common and typically done to satisfy withholding and do not necessarily indicate a change in the insider’s view of the company.